ADVERTISEMENT

Is it a 'senior moment' or early dementia? Addressing memory concerns in older patients

Current Psychiatry. 2016 May;15(5):28-30,32-34,40
Author and Disclosure Information

The prevalence of memory-related issues increases with age. So does concern about dementia. Be prepared to render the best evaluation and advice possible.

It is common for seniors to take a variety of untested and unproven supplements in the hope of preventing or lessening memory problems. In addition to incurring significant costs, the indiscriminate use of supplements poses risks of toxicity, including unintended interactions with prescribed medications. Many older adults do not disclose their use of these supplements to providers because they do not consider them “medicine.”

Labs. The next level of evaluation calls for a basic laboratory workup. Check complete blood count, liver enzymes, thyroid function tests, vitamin D, B12 and folate levels; perform urinalysis and a complete metabolic panel. Look at a general hormone panel; abnormal values could reveal a pituitary adenoma. (In the past 33 years, the first author has found 42 pituitary tumors in the workup of mental status change.)

We use imaging, such as a CT or MRI of the brain, in almost all cases of suspected dementia. Cerebral atrophy, space-occupying lesions, and shifting of the ventricles often correspond with cognitive decline.


Treatment

Effective treatment of dementia remains elusive. Other than for the “reversible dementias,” pharmacotherapy has shown less progress than had been expected. Donepezil, galantamine, rivastigmine, and memantine could slow disease progression in some cases. There have been many studies for dementia preventives and treatments. Extensive reviews and meta-analyses, including those of randomized controlled trials17-19 abound for a variety of herbs, supplements, and antioxidants; none have shown compelling results. Table 2 lists Institute of Medicine recommendations supported by evidence that could reduce effects of cognitive aging.20

Recommendations from collaboration between the National Institute on Aging and the Alzheimer’s Association21 state that research should focus on biomarkers, such as neural substrates or genotypes. Indicators of oxidative stress (cytokines) and inflammation (isoprostanes) show promise as measures of brain changes that correspond with increased risk of AD or other dementias.


Summing up

Older adults are a heterogeneous group. Intellectual capacity does not diminish with advancing age. Many elders now exceed expectations for productivity, athletic ability, scientific achievement, and the creative arts. Others live longer with diminished quality of life, their health compromised by progressive neurodegenerative disease.

Age-associated memory change often is exaggerated and feared by older adults and, regrettably, is associated with inevitable functional impairment and is seen as heralding the loss of autonomy. The worried well are anxious, although the stigma associated with cognitive decline may preclude confiding their concerns.

Providers need the tools and acumen to treat patients along an increasingly long continuum of time, including conveyance of evidence-based encouragement toward optimal health and vitality.


Bottom Line

Variations in cognition occur over the lifespan. Be aware that mild cognitive impairment (MCI) is not a benign change but a harbinger of dementia for most affected people. We are able to differentiate the worried well from patients with MCI. The importance of early treatment for reversible forms of dementia is vital to reducing patient suffering and the overall burden on caregivers. Early identification of MCI will assist further research toward prevention or delay of progression to Alzheimer’s dementia.

Related Resources
  • American Psychological Association. Memory and Aging. www.apa.org/pi/aging/memory-and-aging.pdf.
  • Desai AK, Schwarz L. Subjective cognitive impairment: when to be concerned about ‘senior moments.’ Current Psychiatry. 2011;10(4):31,32,39,40,42,44,A.


Drug Brand Names

Donepezil • Aricept
Galantamine • Reminyl
Memantine • Namenda
Rivastigmine • Exelon


Disclosure
s
The authors report no financial relationships with any company whose products are mentioned in this article or with manufacturers of competing products.